{"id":296414,"date":"2023-04-13T00:00:00","date_gmt":"2023-04-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0025-2023-biopharma-multiple-sclerosis-unmet-need-unmet-need-primary-progressive-multiple\/"},"modified":"2026-03-31T10:34:00","modified_gmt":"2026-03-31T10:34:00","slug":"unnecg0025-2023-biopharma-multiple-sclerosis-unmet-need-unmet-need-primary-progressive-multiple-sclerosis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0025-2023-biopharma-multiple-sclerosis-unmet-need-unmet-need-primary-progressive-multiple-sclerosis-us-eu\/","title":{"rendered":"Multiple Sclerosis &#8211; Unmet Need &#8211; Unmet Need &#8211; Primary-Progressive Multiple Sclerosis (US\/EU)"},"content":{"rendered":"<p>Roche \/ Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (<abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr>)\u2014making it the first agent to approved for this <abbr title=\"multiple sclerosis\">MS<\/abbr> subpopulation. According to Clarivate research and company reports, uptake of the drug in <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr> has been understandably strong, with significant revenue coming from the <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr> market. Nevertheless, opportunity in the space remains because the drug may not be appropriate for all patients. Ocrevus targets neuroinflammation, which is not observed in all <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr> patients, and according to some <abbr title=\"key opinion leader\">KOL<\/abbr>s interviewed by Clarivate, it imparts a modest clinical effect in <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr>. This report will examine neurologists\u2019 satisfaction with Ocrevus and <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s used off-label today in <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr>, and gauge the opportunity and value-drivers for alternatives to treat this underserved <abbr title=\"multiple sclerosis\">MS<\/abbr> subpopulation. Ocrevus could soon face competition in <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr> from Sanofi\u2019s tolebrutinib, Roche\u2019s fenebrutinib, and <span class=\"abbreviation-guard\">AB <\/span>Science\u2019s masitinib. However, with only a handful of therapies aimed at halting disability progression in <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr> in late-phase development, this market segment is primed for new investment and drug discovery.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the top areas of unmet need in <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr>, and which therapies in development, if any, are poised to meet these needs?<\/li>\n<li>Which clinical endpoints and drug attributes are most influential in prescribing for <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr>? How do Ocrevus (the only approved agent) and other <abbr title=\"multiple sclerosis\">MS<\/abbr> <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s perform on these attributes?<\/li>\n<li>What magnitude of reduction in disease progression will result in a novel therapy being considered the gold standard for treating <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr>?<\/li>\n<li>Based on conjoint analysis and <abbr title=\"Target Product Profile\">TPP<\/abbr> simulation, which trade-offs between efficacy, safety, and price are neurologists willing to make for a hypothetical new <abbr title=\"primary-progressive multiple sclerosis\">PP-MS<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 32 European neurologists fielded in January 2023<\/p>\n<p><strong>Key companies:<\/strong> Sanofi, Teva, Novartis, Merck KGaA \/ EMD Serono, Roche \/ Genentech, Biogen<\/p>\n<p><strong>Key drugs:<\/strong> Aubagio, Copaxone \/ glatiramer acetate, Gilenya, Mavenclad, Ocrevus, Tecfidera \/ dimethyl fumarate, Tysabri<\/p>\n","protected":false},"template":"","class_list":["post-296414","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296414\/revisions"}],"predecessor-version":[{"id":296635,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296414\/revisions\/296635"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}